MTNB · Matinas BioPharma Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $1.1M | $3.19M | $33K | $158.33K | $89.81K | $119.75K | $149.69K | $0 | $194.49K | $0 | — | |
| — | $85K | $11.43M | $14.49M | $16.68M | $14.58M | $14.36M | $11.23M | $6.79M | $9.01M | $3.95M | $5.29M | $5.18M | $1.76M | |
| $6.67M | $6.88M | $8.73M | $10.37M | $11.1M | $10.19M | $10.01M | $7.78M | $7.98M | $7.64M | $4.31M | $4.81M | $5.29M | $1.95M | |
| $2000 | $32K | $365K | $385K | $337K | $244K | $231.06K | $205.96K | $218.31K | $100.61K | $52.64K | $43.5K | $41.58K | — | |
| $14.54M | — | — | — | — | — | — | — | — | — | $8.26M | $10.11M | $10.46M | $3.71M | |
| $6.67M | $6.96M | $24.59M | $24.86M | $27.78M | $24.77M | $24.36M | $19.01M | $14.77M | $16.65M | $8.26M | $10.11M | — | — | |
| -$6.67M | -$6.96M | -$24.59M | -$23.77M | -$24.59M | -$24.74M | -$24.21M | -$18.92M | -$14.65M | -$16.5M | -$8.26M | -$9.91M | -$10.46M | -$3.71M | |
| — | — | — | -2168.43% | -771.33% | -74954.55% | -15288.38% | -21067.38% | -12230.94% | -11024.61% | — | -5096.04% | — | — | |
| -$6.67M | -$6.93M | -$24.23M | -$23.38M | -$24.25M | -$24.49M | -$23.98M | -$18.72M | -$14.43M | -$16.4M | -$8.2M | -$9.87M | -$10.42M | — | |
| -$180K | -$261K | $262K | $340K | $102K | $124K | — | $541.3K | $56.55K | $22.03K | -$16.51K | $19.63K | -$25.17K | -$688 | |
| — | — | — | $484K | $3.49M | $1.33M | $1.07M | $1.01M | — | $636.93K | $674.9K | $756.47K | $269.13K | $0 | |
| — | -$10.35M | -$24.33M | -$22.94M | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$80K | — | — | — | — | — | $506.92K | $400K | — | — | $270K | — | |
| -$6.69M | -$10.35M | -$24.25M | -$22.94M | -$21M | -$23.28M | -$22.45M | -$17.37M | -$14.08M | -$15.49M | -$7.6M | -$9.14M | -$10.22M | -$3.71M | |
| — | — | — | -2093.25% | -658.63% | -70554.55% | -14176.98% | -19343.35% | -11760.39% | -10345.91% | — | -4697.01% | — | — | |
| -$7.31M | -$10.96M | -$24.25M | — | -$21M | -$23.68M | -$23.24M | -$18.3M | -$14.99M | -$32.84M | -$11.99M | -$9.14M | — | — | |
| — | -$10.35M | -$24.03M | -$22.34M | -$21.68M | -$23.66M | -$22.22M | -$17.37M | -$14.08M | — | — | — | — | — | |
| USD/shares | -$1.15 | -$2.00 | -$4.98 | -$5.28 | -$5.00 | -$5.50 | — | — | — | — | — | — | — | — |
| USD/shares | -$1.15 | -$2.00 | -$4.98 | -$5.28 | -$5.00 | — | — | — | — | — | — | — | — | — |
| shares | — | 5.47M | 4.87M | 4.35M | 4.34M | 4.2M | 3.94M | 2.9M | 1.96M | 1.81M | 1.15M | 1.03M | 641.53K | 380.03K |
| shares | — | 5.47M | 4.87M | 4.35M | 4.34M | 4.2M | 3.94M | 2.9M | 1.96M | 1.81M | 1.15M | 1.03M | 641.53K | 380.03K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 119 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2020 | FY2019 |
|---|---|---|
| CFF Research Grant Revenue | $125,000 | $89,800 |